PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol

References

• Mueck AO, Ruan X. Benefits and risks during HRT: main safety issue breast cancer. Horm Mol Biol Clin Invest 2011;5:105–16
   PubMedGoogle Scholar
• Seeger H, Mueck AO. Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. J Steroid Biochem Mol Biol 2008;109:11–5
   PubMed Web of Science ®Google Scholar
• Mueck AO, Ruan X, Seeger H, et al. Genomic and non-genomic actions of progestogens in the breast. J Steroid Biochem Mol Biol 2014;142:62–7
   PubMed Web of Science ®Google Scholar
• Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update 2005;11:561–73
   PubMed Web of Science ®Google Scholar
• Shah NR, Borenstein J, Dubois RW. Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 2005;12:668–78
   PubMed Web of Science ®Google Scholar
• Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–27
   PubMed Web of Science ®Google Scholar
• Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011;128:144–56
   PubMed Web of Science ®Google Scholar
• Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027–32
   PubMed Web of Science ®Google Scholar
• Beral V (Collaborative Group on Hormonal Factors in Breast Cancer) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047–59
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354–60
   PubMed Web of Science ®Google Scholar
• Brown SB, Hankinson SE. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids 2015;99:8–10
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors of Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012;13:1141–51
   PubMed Web of Science ®Google Scholar
• Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 2009;9:51–60
   PubMed Web of Science ®Google Scholar
• Sestak I, Cuzick J. Preventive therapy for breast cancer. Curr Oncol Rep 2012;14:568–73
   PubMed Web of Science ®Google Scholar
• Ruan X, Seeger H, Mueck AO. Breast cancer risk during hormone therapy: experimental versus clinical data. Minerva Endocrinol 2012;37:59–74
   PubMed Web of Science ®Google Scholar
• Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005;20:2052–60
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA 2017;318:927–38
   PubMed Web of Science ®Google Scholar
• Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One 2013;8:e78016
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409 10.1136/bmj.e6409
   PubMed Web of Science ®Google Scholar
• Jones ME, Schoemaker MJ, Wright L, et al. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?. Br J Cancer 2016;115:607–15
   PubMed Web of Science ®Google Scholar
• Neubauer H, Ma Q, Zhou J, et al. Possible role of PGRMC1 in breast cancer development. Climacteric 2013;16:509–13
   PubMed Web of Science ®Google Scholar
• Hampton KK, Stewart R, Napier D, et al. PGRMC1 Elevation in Multiple Cancers and Essential Role in Stem Cell Survival. ALC 2015;04:37–51
   Google Scholar
• Crudden G, Loesel R, Craven RJ. Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumor Biol 2005;26:142–6
   PubMed Web of Science ®Google Scholar
• Chen WS, Chen PL, Li J, et al. Lipid synthesis and processing proteins ABHD5, PGRMC1 and squalene synthase can serve as novel immunohistochemical markers for sebaceous neoplasms and differentiate sebaceous carcinoma from sebaceoma and basal cell carcinoma with clear cell features. J Cutan Pathol 2013;40:631–8
   PubMed Web of Science ®Google Scholar
• Zhang D, Xia X, Wang X, et al. PGRMC1 Is a Novel Potential Tumor Biomarker of Human Renal Cell Carcinoma Based on Quantitative Proteomic and Integrative Biological Assessments. PLoS One 2017;12:e170453
   PubMed Web of Science ®Google Scholar
• Neubauer H, Chen R, Schneck H, et al. New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Clin Investig 2011;6:185–92
   PubMedGoogle Scholar
• Ruan X, Neubauer H, Yang Y, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric 2012;15:467–72
   PubMed Web of Science ®Google Scholar
• Ruan X, Schneck H, Schultz S, et al. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells. Gynecol Endocrinol 2012;28:863–6
   PubMed Web of Science ®Google Scholar
• Zhou J, Yu Q, Chen R, et al. Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1. Maturitas 2013;76:129–33
   PubMed Web of Science ®Google Scholar
• Schneck H, Ruan X, Seeger H, et al. Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells. Gynecol Endocrinol 2013;29:160–3
   PubMed Web of Science ®Google Scholar
• Neubauer H, Ruan X, Schneck H, et al. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy. Menopause 2013;20:504–10
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ruan X, Willibald M, et al. May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer? Gynecol Endocrinol 2016;32:58–60
   PubMed Web of Science ®Google Scholar
• Ruan X, Zhang Y, Mueck AO, et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer. Menopause 2017;24:203–9
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ruan X, Wang H, et al. The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: A xenograft model. Maturitas 2017;102:26–33
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ. Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women's Health Initiative trial be explained by progesterone receptor membrane component 1? Menopause 2011;18:833–4
   PubMed Web of Science ®Google Scholar
• Price T. Progesterone receptor membrane component 1: is metabolism integral to its function and what other steroids are involved? Menopause 2013;20:486–7
   PubMed Web of Science ®Google Scholar
• Neubauer H, Yang Y, Seeger H, et al. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause 2011;18:845–50
   PubMed Web of Science ®Google Scholar
• Neubauer H, Adam G, Seeger H, et al. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric 2009;12:230–9
   PubMed Web of Science ®Google Scholar
• Lodde V, Peluso JJ. A novel role for progesterone and progesterone receptor membrane component 1 in regulating spindle microtubule stability during rat and human ovarian cell mitosis. Biol Reprod 2011;84:715–22
   PubMed Web of Science ®Google Scholar
• Ahmed IS, Rohe HJ, Twist KE, et al. Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule. J Pharmacol Exp Ther 2010;333:564–73
   PubMed Web of Science ®Google Scholar
• Prifti S, Mall P, Strowitzki T, et al. Synthetic estrogens-mediated activation of JNK intracellular signaling molecule. Gynecol Endocrinol 2001;15:135–41
   PubMed Web of Science ®Google Scholar
• Yu S, Kim T, Yoo KH, et al. The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer. Biochem Biophys Res Commun 2017;486:752–8
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Seeger H, Mueck AO. Proliferative effects of estradiol- or ethinylestradiol-progestogen combinations on human breast cancer cells in an intermitted and a long-term regimen. Horm Metab Res 2012;44:415–21
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H, Wallwiener D. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric 2003;6:221–7
   PubMed Web of Science ®Google Scholar
• Bhavnani BR, Stanczyk FZ. Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action. J Steroid Biochem Mol Biol 2014;142:16–29
   PubMed Web of Science ®Google Scholar
• Blankenstein MA, Maitimu-Smeele I, Donker GH, et al. On the significance of in situ production of oestrogens in human breast cancer tissue. J Steroid Biochem Mol Biol 1992;41:891–6
   PubMed Web of Science ®Google Scholar
• Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 2006-12-0110:515–27
   PubMed Web of Science ®Google Scholar
• Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer RES 2011;13:215 2011-08-12
   PubMed Web of Science ®Google Scholar